Advertisement
UK markets close in 6 hours 3 minutes

  • FTSE 100

    8,090.04
    +49.66 (+0.62%)
     

  • FTSE 250

    19,721.89
    +2.52 (+0.01%)
     

  • AIM

    755.33
    +0.64 (+0.08%)
     

  • GBP/EUR

    1.1672
    +0.0027 (+0.23%)
     

  • GBP/USD

    1.2519
    +0.0056 (+0.45%)
     

  • Bitcoin GBP

    51,168.46
    -1,961.73 (-3.69%)
     

  • CMC Crypto 200

    1,365.31
    -17.27 (-1.25%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.84
    +0.03 (+0.04%)
     

  • GOLD FUTURES

    2,338.40
    0.00 (0.00%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,985.43
    -103.27 (-0.57%)
     

  • CAC 40

    8,051.71
    -40.15 (-0.50%)
     
Property:

How to sell your home

Top tips from property investors

argenx to Present at Upcoming Investor Conferences

argenx SE
·1-min read


November 10, 2021

Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in several upcoming conferences:

  • Guggenheim Healthcare Talks | Idea Forum | 3rd Annual Neuro/Immunology Day. Fireside chat on Monday, November 15, 2021 at 9:40 a.m. ET.

  • Evercore ISI 4th Annual HealthCONx Conference. Fireside chat on Tuesday, November 30, 2021 at 12:35 p.m. ET.

  • Piper Sandler 33rd Annual Healthcare Conference. Pre-recorded fireside chat will be made available on November 22, 2021 at 10:00 a.m. ET.

Additional information regarding these events will be available on the Investors section of the argenx website at argenx.com/investors.

ADVERTISEMENT

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, Japan, and Switzerland. For more information, visit www.argenx.com and follow us on LinkedIn and Twitter.

For further information, please contact:

Media:
Kelsey Kirk
kkirk@argenx.com

Joke Comijn (EU)
jcomijn@argenx.com

Investors:

Beth DelGiacco
bdelgiacco@argenx.com

Michelle Greenblatt
mgreenblatt@argenx.com